Circulating tumour DNA for detecting minimal residual disease in multiple myeloma

Circulating tumour DNA faithfully recapitulates somatic mutations detected in bone marrow aspirates from patients with newly diagnosed or relapsed/recurrent myeloma. Extending these methods to enable detection of minimal residual disease will require increased sensitivity and breadth of genomic assays to maximize information content from small quantities of cell-free DNA; as well as definition of a clinically-meaningful ctDNA concentration in comparison with conventional bone marrow cell-count thresholds.

Source: Seminars in Hematology - March 7, 2018 Category: Hematology Authors: Trevor J. Pugh Tags: 55/2 Disease Monitoring in Myeloma Source Type: research